Clinical Trials

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

78 enrolled

HER2 Positive Metastatic Breast Cancer

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

120 enrolled

Breast Neoplasms

NCT05823623 2023-09-14

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

30 enrolled

Breast Neoplasms

NCT05880927 2023-05-30

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

150 enrolled

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

41 enrolled

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

30 enrolled

Breast Neoplasms

NCT05764941 2023-03-27

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

59 enrolled

Breast Neoplasms

NCT04582968 2023-01-18

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

39 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03863223 2022-11-23

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

590 enrolled

Breast Neoplasms

NCT05621434 2022-11-18

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

63 enrolled

Breast Neoplasms

NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

279 enrolled

HER2 Positive Metastatic Breast Cancer

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT05561686 2022-09-30

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05429294 2022-06-23

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

209 enrolled

HER2-positive Breast Cancer

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

120 enrolled

HER2+ Breast Cancer

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

240 enrolled

Breast Neoplasms

NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

30 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05030519 2022-03-02

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

50 enrolled

Breast Neoplasms

NCT05255523 2022-02-24

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

60 enrolled

Advanced Breast Cancer

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

65 enrolled

Stomach Neoplasms

NCT05087706 2021-10-21

MAPS

182 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05076695 2021-10-13

NeoTPPF

37 enrolled

Estrogen Receptor-positive Breast Cancer

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

68 enrolled

Advanced Breast Cancer

NCT04380012 2021-07-15

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Breast Neoplasms

NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

60 enrolled

Digestive System Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

60 enrolled

Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

120 enrolled

CNS

Brain Neoplasms

NCT04900311 2021-05-25

Pyramid

490 enrolled

HER2+ Early or Locally Advanced Breast Cancer

NCT03980054 2021-05-24

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

1,192 enrolled

Breast Neoplasms

NCT04899128 2021-05-24

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Breast Neoplasms

NCT04858516 2021-04-26

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

57 enrolled

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

NCT02500199 2021-02-01

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Phase 1 Unknown

50 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04609540 2020-12-16

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

200 enrolled

Breast Neoplasms

NCT04659499 2020-12-09

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

261 enrolled

Breast Neoplasms

NCT04639271 2020-11-20

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Neoplasms

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

240 enrolled

HER2 Positive Metastatic Breast Cancer

NCT04255056 2020-02-07

PRETTY

27 enrolled

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04236310 2020-01-22

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

37 enrolled

Breast Neoplasms

NCT04227041 2020-01-14

A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

34 enrolled